TY - JOUR T1 - Plasma S-Adenosylmethionine is Associated with Lung Injury in COVID-19 JF - medRxiv DO - 10.1101/2021.09.23.21262822 SP - 2021.09.23.21262822 AU - Evgeny Kryukov AU - Alexander Ivanov AU - Vladimir Karpov AU - Valery Alexandrin AU - Alexander Dygai AU - Maria Kruglova AU - Gennady Kostiuchenko AU - Sergei Kazakov AU - Aslan Kubatiev Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/09/24/2021.09.23.21262822.abstract N2 - Objective S-Adenosylmethionine (SAM) and S-adenosylhomocysteine (SAH) are indicators of global transmethylation and may play an important role as markers of severity of COVID-19.Methods The levels of plasma SAM and SAH were determined in patients admitted with COVID-19 (n = 56, mean age = 61). Lung injury was identified by computed tomography (CT) in accordance with the CT0-4 classification.Results SAM was found to be a potential marker of lung damage risk in COVID-19 patients (SAM > 80 nM; CT3,4 vs. CT 0-2: relative ratio (RR) was 3.0; p = 0.0029). SAM/SAH > 6.0 was also found to be a marker of lung injury (CT2-4 vs. CT0,1: RR = 3.47, p = 0.0004). Interleukin-6 (IL-6) levels were associated with SAM (ρ = 0.44, p = 0.01) and SAH (ρ = 0.534, p = 0.001) levels.Conclusions High SAM levels and high methylation index are associated with the risk of lung injury in COVID-19 patients. The association of SAM and SAH with IL-6 indicates an important role of transmethylation in the development of cytokine imbalance in COVID-19 cases.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Russian Foundation for Basic Research (RFBR), project № 20-04-60251\20.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study included 56 COVID-19 patients who were admitted in the pulmonary department of the Burdenko Main Military Clinical Hospital from September 2020 to December 2020. Approval for this study was given from the ethics committee of Burdenko Main Military Clinical Hospital. Informed written consent was obtained from each patient. The reporting of this study conforms to STROBE guidelines.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe anonymized data used to support the findings of this study are available from the corresponding author upon request. https://figshare.com/articles/dataset/SAM_SAH_Covid_patients_data_xls/16539591 2’-OMTase2’-O-methyltransferaseAdoadenosineALTalanine aminotransferaseASTaspartate aminotransferaseCRBC-reactive proteinCOVID-19coronavirus disease 2019CTcomputed tomographyEDendothelial dysfunctionESRthe erythrocyte sedimentation rateGSHglutathioneHCThematocritHcyhomocysteineHGBhemoglobinIL-6interleukin-6LIleukocyte indexLPSlipopolysaccharideMAPKmitogen-activated protein kinasesMCHmean erythrocyte hemoglobinMCHCmean corpuscular hemoglobin concentrationMCVmean erythrocyte volumeN7-Mtase(guanine-N7)-methyltransferaseNspnonstructural proteinsORodds ratioPLTplateletsRBCred blood cellsRRrelative riskSAHS-adenosylhomocysteineSAHHSAH hydrolaseSAMS-adenosylmethionineSARS-CoV-2acute respiratory syndrome coronavirus-2WBCwhite blood cells ER -